Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.47 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359316 | 0.82 | CNR2 (0.53) | CNR2KMT2AMEN1CNR1TRPV1 | |
| SCHEMBL3879676 | 0.78 | GRM4 (0.64) | KMT2AMEN1NPC1RAB9ATRPV1 | |
| SCHEMBL3891697 | 0.77 | MEN1 (0.62) | KMT2AMEN1NPC1RAB9ATRPV1 | |
| SCHEMBL6005094 | 0.76 | MAOB (0.61) | HTR2CMAOBKMT2ANPC1 | |
| SCHEMBL9165502 | 0.76 | HTR2C (0.61) | HTR2CMAOBKMT2AMEN1NPC1 | |
| SCHEMBL2661003 | 0.76 | NPC1 (0.83) | HTR2CKMT2AMEN1NPC1RAB9A | |
| SCHEMBL18132530 | 0.76 | MEN1 (0.61) | KMT2AMEN1NPC1RAB9ATRPV1 | |
| SCHEMBL7101847 | 0.74 | PABPC1 (0.79) | KMT2AMEN1NPC1RAB9ATRPV1 | |
| SCHEMBL29176621 | 0.74 | MAOB (0.62) | MAOBKMT2AMEN1AURKA | |
| SCHEMBL4811502 | 0.74 | MAOB (0.84) | MAOBKMT2AMEN1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | claimed |
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | HTR2C 156/4885MAOB 1213/4885CNR2 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.